## Follicular Phase Endocrine Characteristics during Ovari Antagonist Cotreatment for IVF: RCT Comparing recFSI

Journal of Clinical Endocrinology and Metabolism 96, 1122-1128 DOI: 10.1210/jc.2010-2239

**Citation Report** 

#	Article	IF	CITATIONS
1	Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Current Opinion in Obstetrics and Gynecology, 2011, 23, 238-244.	2.0	37
3	IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and Obstetrics, 2012, 286, 763-769.	1.7	18
4	Initiation of ovarian stimulation independent of the menstrual cycle: a case–control study. Archives of Gynecology and Obstetrics, 2013, 288, 901-904.	1.7	39
5	Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6. Fertility and Sterility, 2013, 100. 867-874.	1.0	15
6	Mild Ovarian Stimulation for in vitro Fertilization: Are We Ready to Change? A Meta-Analysis. Gynecologic and Obstetric Investigation, 2013, 76, 233-240.	1.6	17
7	Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot study. Human Reproduction, 2014, 29, 1500-1507.	0.9	8
8	Minimal or Mild Ovarian Stimulation for IVF: Overview. , 2017, , 195-209.		1
9	r-FSH total dose is negatively associated to live birth rate: a retrospective analysis. Fertility and Sterility, 2017, 108, e22.	1.0	Ο
10	Highly purified human menotropin (HP-HMG) versus recombinant follicle stimulating hormone (RFSH) in high responders undergoing in vitro fertilization (IVF): MEGASET-HR trial outcomes. Fertility and Sterility, 2017, 108, e21-e22.	1.0	3
11	A randomized controlled trial with addition of letrozole as an adjunct to FSH in high responders in stimulated IVF cycles show negative impact of ovarian stimulation on the endomterium. Fertility and Sterility, 2017, 108, e22.	1.0	0
12	Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors. Reproductive BioMedicine Online, 2017, 35, 425-431.	2.4	8
13	Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study. Reproductive Biology and Endocrinology, 2019, 17, 43.	3.3	17
14	Controlled Ovarian Stimulation Strategies for IVF and Programing Cycles with Steroid Pretreatment. , 2019, , 80-93.		0
15	GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation. Gynecological Endocrinology, 2019, 35, 309-313.	1.7	25
16	LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective. Gynecologic and Obstetric Investigation, 2020, 85, 307-311.	1.6	9
17	ESHRE guideline: ovarian stimulation for IVF/ICSIâ€. Human Reproduction Open, 2020, 2020, hoaa009.	5.4	205
18	The Importance of Mid-Follicular Phase Luteinizing Hormone Rise in GnRH Antagonist-Based Ovarian Stimulation for IVF. Gynecologic and Obstetric Investigation, 2020, 85, 184-188.	1.6	4
19	Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis. Human Reproduction Update, 2021, 27, 229-253.	10.8	48

	CITATIO	TION REPORT		
#	Article	IF	Citations	
20	Step-Down of FSH- Dosage During Ovarian Stimulation – Basic Lessons to Be Learnt From a Randomized Controlled Trial. Frontiers in Endocrinology, 2021, 12, 661707.	3.5	7	
21	Effects of increasing serum luteinizing hormone levels during early phase of the gonadotropin-releasing hormone antagonist protocol on clinical outcomes of the <i>in vitro</i> fertilization cycle. Gynecological Endocrinology, 2022, 38, 135-139.	1.7	4	
22	Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle. , 2013, , 31-42.		15	
23	Hypothalamic–Pituitary–Ovarian Axis and Control of the Menstrual Cycle. , 2017, , 1-17.		2	
24	Optimisation of the follicular phase in IVF/ICSI. Facts, Views & Vision in ObGyn, 2012, 4, 203-12.	1.1	3	
25	Endometrial Preparation for Frozen–Thawed Embryo Transfer With or Without Pretreatment With GnRH Agonist: A Randomized Controlled Trial at Two Centers. Frontiers in Endocrinology, 2021, 12, 722253.	3.5	11	
26	Mild Approaches in Ovarian Stimulation. , 2022, , 36-46.		0	
27	Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?. Journal of Clinical Medicine, 2023, 12, 1008.	2.4	2	
28	Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study. Diagnostics, 2023, 13, 1249.	2.6	0	
29	Effect of trigger day serum luteinising hormone levels on the in-vitro fertilization outcome: an observational study. Obstetrics and Gynecology Science, 2024, 67, 235-242.	1.6	0	